{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:09:28Z","timestamp":1767704968730,"version":"3.48.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Duke Center for Brain and Spine Metastasis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05332-2","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:11:47Z","timestamp":1762942307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and survival of adolescent and young adults with brain metastases compared to older adults"],"prefix":"10.1007","volume":"176","author":[{"given":"Michael R.","family":"Kann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan S.","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia R.","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quinn T.","family":"Ostrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"5332_CR1","doi-asserted-by":"publisher","unstructured":"GBD (2019) Adolescent Young Adult Cancer Collaborators. In 2019: a systematic analysis for the global burden of disease study 2019, (in eng). Lancet Oncol 23(1):27\u201352. https:\/\/doi.org\/10.1016\/s1470-2045(21)00581-7","DOI":"10.1016\/s1470-2045(21)00581-7"},{"key":"5332_CR2","doi-asserted-by":"publisher","unstructured":"Wang X, Langevin AM, Houghton PJ, Zheng S (Nov 24 2022) Genomic disparities between cancers in adolescent and young adults and in older adults, (in eng), Nat Commun 13(1):7223. https:\/\/doi.org\/10.1038\/s41467-022-34959-2","DOI":"10.1038\/s41467-022-34959-2"},{"key":"5332_CR3","doi-asserted-by":"publisher","unstructured":"Keegan TH et al (Apr 1 2016) Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults, (in eng), Cancer 122(7):1009-16. https:\/\/doi.org\/10.1002\/cncr.29869","DOI":"10.1002\/cncr.29869"},{"key":"5332_CR4","doi-asserted-by":"publisher","unstructured":"Bleyer A (May 1 2005) The adolescent and young adult gap in cancer care and outcome, current problems in pediatric and adolescent health care 35(5):182\u2013217. https:\/\/doi.org\/10.1016\/j.cppeds.2005.02.001","DOI":"10.1016\/j.cppeds.2005.02.001"},{"issue":"2","key":"5332_CR5","doi-asserted-by":"publisher","first-page":"pkz031","DOI":"10.1093\/jncics\/pkz031","volume":"3","author":"DJ Moke","year":"2019","unstructured":"Moke DJ et al (2019) Emerging cancer survival trends, disparities, and priorities in adolescents and young adults: a California Cancer Registry-Based study. JNCI Cancer Spectr 3(2):pkz031. https:\/\/doi.org\/10.1093\/jncics\/pkz031","journal-title":"JNCI Cancer Spectr"},{"key":"5332_CR6","doi-asserted-by":"publisher","unstructured":"Bhutada JKS, Hwang AE, Liu L, Tsai KY, Deapen D, Freyer DR (Oct 8 2022) Risk of presenting with poor-prognosis metastatic cancer in adolescents and young adults: a population-based study, (in eng), Cancers (Basel) 14(19). https:\/\/doi.org\/10.3390\/cancers14194932","DOI":"10.3390\/cancers14194932"},{"key":"5332_CR7","doi-asserted-by":"publisher","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (Jul 15 2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance System, (in eng). J Clin Oncol 22(14):2865\u20132872. https:\/\/doi.org\/10.1200\/jco.2004.12.149","DOI":"10.1200\/jco.2004.12.149"},{"key":"5332_CR8","doi-asserted-by":"publisher","unstructured":"H\u00fcgel M et al (Aug 30 2023) Long-term survival in patients with brain metastases\u2014clinical characterization of a rare scenario, Strahlentherapie und Onkologie. https:\/\/doi.org\/10.1007\/s00066-023-02123-4","DOI":"10.1007\/s00066-023-02123-4"},{"key":"5332_CR9","doi-asserted-by":"publisher","unstructured":"Mallin K et al (Jun 2019) Incident cases captured in the National cancer database compared with those in U.S. population based central cancer registries in 2012\u20132014, (in eng). Ann Surg Oncol 26(6):1604\u20131612. https:\/\/doi.org\/10.1245\/s10434-019-07213-1","DOI":"10.1245\/s10434-019-07213-1"},{"key":"5332_CR10","doi-asserted-by":"publisher","unstructured":"Liu L et al (Nov 15 2020) Radiotherapy in combination with systemic therapies for brain metastases: current status and progress, (in eng), Cancer Biol Med 17(4):910\u2013922. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0109","DOI":"10.20892\/j.issn.2095-3941.2020.0109"},{"key":"5332_CR11","doi-asserted-by":"publisher","unstructured":"Pe\u00f1a-Pino I, Chen CC (Jun 2023) Stereotactic radiosurgery as treatment for brain metastases: an Update, (in eng). Asian J Neurosurg 18(2):246\u2013257. https:\/\/doi.org\/10.1055\/s-0043-1769754","DOI":"10.1055\/s-0043-1769754"},{"key":"5332_CR12","doi-asserted-by":"publisher","unstructured":"Vogelbaum MA et al (Feb 10 2022) Treatment for brain metastases: ASCO-SNO-ASTRO Guideline, (in eng). J Clin Oncol 40(5):492\u2013516. https:\/\/doi.org\/10.1200\/jco.21.02314","DOI":"10.1200\/jco.21.02314"},{"key":"5332_CR13","doi-asserted-by":"publisher","unstructured":"Gondi V et al (Jul-Aug 2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline, (in eng), Pract Radiat Oncol 12(4):265\u2013282. https:\/\/doi.org\/10.1016\/j.prro.2022.02.003","DOI":"10.1016\/j.prro.2022.02.003"},{"key":"5332_CR14","doi-asserted-by":"publisher","unstructured":"Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V (Feb 10 2018) Whole-brain radiotherapy for brain metastases: evolution or revolution? (in eng), J Clin Oncol 36(5):483\u2013491. https:\/\/doi.org\/10.1200\/jco.2017.75.9589","DOI":"10.1200\/jco.2017.75.9589"},{"key":"5332_CR15","doi-asserted-by":"publisher","unstructured":"Ladbury C et al (2024) Stereotactic radiosurgery in the management of brain metastases: a case-based radiosurgery society practice guideline. Adv Radiat Oncol 9(3). https:\/\/doi.org\/10.1016\/j.adro.2023.101402","DOI":"10.1016\/j.adro.2023.101402"},{"issue":"7","key":"5332_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jamaoncol.2021.1262","volume":"7","author":"WC Chen","year":"2021","unstructured":"Chen WC et al (May 1 2021) Efficacy and safety of stereotactic radiosurgery for brainstem metastases: a systematic review and meta-analysis. JAMA Oncol 7(7):1033\u20131040. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1262","journal-title":"JAMA Oncol"},{"key":"5332_CR17","doi-asserted-by":"publisher","unstructured":"Mansouri A et al (2025) Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care. Nat Reviews Clin Oncol 22(5):327\u2013347. https:\/\/doi.org\/10.1038\/s41571-025-01013-1","DOI":"10.1038\/s41571-025-01013-1"},{"key":"5332_CR18","doi-asserted-by":"publisher","unstructured":"Won YK et al (Sep 2015) Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer, (in eng), Radiat Oncol J 33(3):207\u2009\u2013\u200916. https:\/\/doi.org\/10.3857\/roj.2015.33.3.207","DOI":"10.3857\/roj.2015.33.3.207"},{"key":"5332_CR19","doi-asserted-by":"publisher","unstructured":"Crooks J, Shepard M, Wegner RE (Dec 1 2023) Treatment trends in brain metastases from testicular cancer in the United States, (in eng), CNS Oncol 12(4):Cns104. https:\/\/doi.org\/10.2217\/cns-2023-0008","DOI":"10.2217\/cns-2023-0008"},{"key":"5332_CR20","doi-asserted-by":"publisher","unstructured":"Almeida ND et al (Oct 21 2024) Stereotactic radiosurgery for intracranial breast metastases: a systematic review and meta-analysis, (in eng), Cancers (Basel) 16(20). https:\/\/doi.org\/10.3390\/cancers16203551","DOI":"10.3390\/cancers16203551"},{"issue":"3","key":"5332_CR21","first-page":"181","volume":"4","author":"HP Bagshaw","year":"2016","unstructured":"Bagshaw HP, Ly D, Suneja G, Jensen RL, Shrieve DC (2016) Local control of melanoma brain metastases treated with stereotactic radiosurgery, (in eng). J Radiosurg SBRT 4(3):181\u2013190","journal-title":"J Radiosurg SBRT"},{"key":"5332_CR22","doi-asserted-by":"publisher","unstructured":"Tsang DS, Murphy E, Salerno KE, Parkes J, Hiniker SM, Braunstein S (Sep 1 2025) Stereotactic radiation therapy in children and young adults: can we apply adult treatment paradigms? Int J Radiation Oncology*Biology*Physics 123(1):43\u201353. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.011","DOI":"10.1016\/j.ijrobp.2025.05.011"},{"key":"5332_CR23","doi-asserted-by":"publisher","unstructured":"Murphy ES et al (Mar 2016) Radiosurgery for pediatric brain tumors, (in eng), Pediatr Blood Cancer 63(3):398\u2013405. https:\/\/doi.org\/10.1002\/pbc.25831","DOI":"10.1002\/pbc.25831"},{"key":"5332_CR24","doi-asserted-by":"publisher","unstructured":"Murphy ES et al (Feb 10 2025) Pediatric cranial stereotactic radiosurgery: meta-analysis and international stereotactic radiosurgery society practice guidelines, (in eng). Neuro Oncol, 27, 2, pp. 517\u2013532. https:\/\/doi.org\/10.1093\/neuonc\/noae204","DOI":"10.1093\/neuonc\/noae204"},{"key":"5332_CR25","doi-asserted-by":"publisher","unstructured":"Mustafayev K et al (2025) Prognostic factors for brain metastasis in adolescent and young adult patients. J Clin Oncol 43(16_suppl):e14011-e14011. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e14011","DOI":"10.1200\/JCO.2025.43.16_suppl.e14011"},{"key":"5332_CR26","doi-asserted-by":"publisher","unstructured":"van der Kooij MK et al (2020) Age does matter in adolescents and young adults versus older adults with advanced melanoma; a national cohort study comparing tumor characteristics, treatment pattern, toxicity and response, (in eng), Cancers (Basel) 12(8):Jul 27. https:\/\/doi.org\/10.3390\/cancers12082072","DOI":"10.3390\/cancers12082072"},{"key":"5332_CR27","doi-asserted-by":"publisher","unstructured":"Harary M, Reardon DA, Iorgulescu JB (Jun 2019) Efficacy and safety of immune checkpoint blockade for brain metastases, (in eng), CNS Oncol 8(2):Cns33. https:\/\/doi.org\/10.2217\/cns-2018-0018","DOI":"10.2217\/cns-2018-0018"},{"key":"5332_CR28","doi-asserted-by":"publisher","unstructured":"Tawbi HA et al (Aug 23 2018) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, (in eng), N Engl J Med 379(8):722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453","DOI":"10.1056\/NEJMoa1805453"},{"key":"5332_CR29","doi-asserted-by":"publisher","unstructured":"Iorgulescu JB et al (Sep 2018) Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort, (in eng), Cancer Immunol Res 6(9):1039\u20131045. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0067","DOI":"10.1158\/2326-6066.Cir-18-0067"},{"key":"5332_CR30","doi-asserted-by":"publisher","unstructured":"Hulsbergen AFC et al (Sep 1 2020) Programmed death receptor ligand one expression may independently predict survival in patients with non-small cell lung carcinoma brain metastases receiving immunotherapy, (in eng). Int J Radiat Oncol Biol Phys 108(1):258\u2013267. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.04.018","DOI":"10.1016\/j.ijrobp.2020.04.018"},{"key":"5332_CR31","doi-asserted-by":"publisher","unstructured":"Ott PA, Hodi FS, Robert C (Oct 1 2013) CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients, (in eng). Clin Cancer Res 19:5300\u20135309. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0143","DOI":"10.1158\/1078-0432.Ccr-13-0143"},{"key":"5332_CR32","doi-asserted-by":"publisher","unstructured":"Saberian C, Sperduto P, Davies MA (Nov 2021) Targeted therapy strategies for melanoma brain metastasis, (in eng), Neurooncol Adv 3(Suppl 5):v75-v85. https:\/\/doi.org\/10.1093\/noajnl\/vdab131","DOI":"10.1093\/noajnl\/vdab131"},{"key":"5332_CR33","doi-asserted-by":"publisher","unstructured":"Yang X, Zeng Y, Tan Q, Huang Z, Jia J, Jiang G (2022) Efficacy of PD-1\/PD-L1 inhibitors versus chemotherapy in lung cancer with brain metastases: a systematic review and meta-analysis, (in eng), J Immunol Res 4518898. https:\/\/doi.org\/10.1155\/2022\/4518898","DOI":"10.1155\/2022\/4518898"},{"key":"5332_CR34","doi-asserted-by":"publisher","unstructured":"Eroglu Z, Topcu TO, Yu HM, Margolin KA (2022) How I treat brain metastases of melanoma. ESMO Open 7(6):100598, 2022\/12\/01\/. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100598","DOI":"10.1016\/j.esmoop.2022.100598"},{"key":"5332_CR35","doi-asserted-by":"publisher","unstructured":"Long GV et al (Nov 13 2014) Combined BRAF and MEK Inhibition versus BRAF Inhibition alone in melanoma, (in eng). N Engl J Med 371(20):1877\u20131888. https:\/\/doi.org\/10.1056\/NEJMoa1406037","DOI":"10.1056\/NEJMoa1406037"},{"key":"5332_CR36","doi-asserted-by":"publisher","unstructured":"Flaherty KT et al (Nov 1 2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, (in eng), N Engl J Med 367(18):1694\u2009\u2013\u2009703. https:\/\/doi.org\/10.1056\/NEJMoa1210093","DOI":"10.1056\/NEJMoa1210093"},{"key":"5332_CR37","doi-asserted-by":"publisher","unstructured":"Menzies AM, Long GV (Apr 15 2014) Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma, (in eng), Clin Cancer Res 20(8)2035-43. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2054","DOI":"10.1158\/1078-0432.Ccr-13-2054"},{"key":"5332_CR38","doi-asserted-by":"publisher","unstructured":"In GK et al (2024) Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma\u2606, ESMO Real World Data and Digital Oncology. 6:100071, 2024\/12\/01\/. https:\/\/doi.org\/10.1016\/j.esmorw.2024.100071","DOI":"10.1016\/j.esmorw.2024.100071"},{"key":"5332_CR39","doi-asserted-by":"publisher","unstructured":"Paisana E et al (2025) Immunotherapy in lung cancer brain metastases, npj Precis Oncol. 9(1):130, 2025\/05\/06. https:\/\/doi.org\/10.1038\/s41698-025-00901-0","DOI":"10.1038\/s41698-025-00901-0"},{"key":"5332_CR40","doi-asserted-by":"publisher","unstructured":"Thomas NJ et al (Jan 1 2022) Brain Metastases in EGFR- and ALK-Positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation, J Thorac Oncol 17(1):116\u201329. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.009","DOI":"10.1016\/j.jtho.2021.08.009"},{"issue":"9","key":"5332_CR41","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1001\/jamaoncol.2017.1047","volume":"3","author":"P Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez P, Mak RH, Oxnard GR (2017) Targeted therapy as an alternative to Whole-Brain radiotherapy in EGFR-Mutant or ALK-Positive Non\u2013Small-Cell lung cancer with brain metastases. JAMA Oncol 3(9):1274\u20131275. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1047","journal-title":"JAMA Oncol"},{"key":"5332_CR42","doi-asserted-by":"publisher","unstructured":"Mandal\u00e0 M et al (Nov 2024) Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study), (in eng). Eur J Cancer 211:114305. https:\/\/doi.org\/10.1016\/j.ejca.2024.114305","DOI":"10.1016\/j.ejca.2024.114305"},{"key":"5332_CR43","doi-asserted-by":"publisher","unstructured":"Sheth Bhutada JK, Hwang AE, Liu L, Tsai KY, Deapen D, Freyer DR (Apr 1 2022) Survival of adolescents and young adults with prevalent poor-prognosis metastatic cancers: a population-based study of contemporary patterns and their implications, (in eng). Cancer Epidemiol Biomarkers Prev 31(4):900\u2013908. https:\/\/doi.org\/10.1158\/1055-9965.Epi-21-0913","DOI":"10.1158\/1055-9965.Epi-21-0913"},{"key":"5332_CR44","doi-asserted-by":"publisher","unstructured":"Yamasaki F (Mar 2022) Adolescent and young adult brain tumors: current topics and review, (in eng). Int J Clin Oncol 27(3):457\u2013464. https:\/\/doi.org\/10.1007\/s10147-021-02084-7","DOI":"10.1007\/s10147-021-02084-7"},{"key":"5332_CR45","doi-asserted-by":"publisher","unstructured":"Tricoli JV, Bleyer A (Nov\/Dec 2018) Adolescent and young adult cancer biology, (in eng). Cancer J 24(6):267\u2013274. https:\/\/doi.org\/10.1097\/ppo.0000000000000343","DOI":"10.1097\/ppo.0000000000000343"},{"key":"5332_CR46","doi-asserted-by":"publisher","unstructured":"Achrol AS et al (Jan 17 2019) Brain metastases, (in eng). Nat Rev Dis Primers 5(1):5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y","DOI":"10.1038\/s41572-018-0055-y"},{"key":"5332_CR47","doi-asserted-by":"publisher","unstructured":"Kim J, Hurria A (Dec 1 2013) Determining chemotherapy tolerance in older patients with cancer, (in eng), J Natl Compr Canc Netw 11(12):1494\u2009\u2013\u2009502. https:\/\/doi.org\/10.6004\/jnccn.2013.0176","DOI":"10.6004\/jnccn.2013.0176"},{"key":"5332_CR48","doi-asserted-by":"publisher","unstructured":"Krok-Schoen JL, Fisher JL, Baltic RD, Paskett ED (Nov 2016) White-Black differences in cancer incidence, stage at diagnosis, and survival among adults aged 85 years and older in the United States, (in eng). Cancer Epidemiol Biomarkers Prev 25(11):1517\u20131523. https:\/\/doi.org\/10.1158\/1055-9965.Epi-16-0354","DOI":"10.1158\/1055-9965.Epi-16-0354"},{"key":"5332_CR49","doi-asserted-by":"publisher","unstructured":"Akinyemiju T, Sakhuja S, Waterbor J, Pisu M, Altekruse SF (Apr 2018) Racial\/ethnic disparities in de Novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer. (in eng) Cancer Med 7(4):1183\u20131193. https:\/\/doi.org\/10.1002\/cam4.1322","DOI":"10.1002\/cam4.1322"},{"key":"5332_CR50","doi-asserted-by":"publisher","unstructured":"Freedland SJ et al (2023) The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis 26(3):461\u2013474, 2023\/09\/01 https:\/\/doi.org\/10.1038\/s41391-023-00710-1","DOI":"10.1038\/s41391-023-00710-1"},{"key":"5332_CR51","doi-asserted-by":"publisher","unstructured":"Iorgulescu JB (Jul 1 2023) Reporting of immunotherapy and biologic therapy in the national cancer database, (in eng), JAMA Oncol 9(7):1003. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0781","DOI":"10.1001\/jamaoncol.2023.0781"},{"key":"5332_CR52","doi-asserted-by":"publisher","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY (Mar 2008) The national cancer data base: a powerful initiative to improve cancer care in the United States, (in eng), Ann Surg Oncol 15(3):683\u2009\u2013\u200990. https:\/\/doi.org\/10.1245\/s10434-007-9747-3","DOI":"10.1245\/s10434-007-9747-3"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05332-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:50Z","timestamp":1767702890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05332-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5332"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05332-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The NCDB Participant User Files contain deidentified national data for which consenting was not applicable and which are not considered human subjects research, so this study was exempt from institutional review board evaluation. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This work was presented in part at the Society for Neuro-Oncology (SNO) Annual Meeting 2021. and the Brain Tumor Epidemiology Consortium (BTEC) Annual Meeting 2025.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}